| Dr Timothy Brian Lumpkin, MD | |
|
12300 Mccracken Rd Ste 259, Garfield Heights, OH 44125-2914 | |
| (216) 587-8830 | |
| (216) 587-8944 |
| Full Name | Dr Timothy Brian Lumpkin |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 11 Years |
| Location | 12300 Mccracken Rd Ste 259, Garfield Heights, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427497791 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RP1001X | Internal Medicine - Pulmonary Disease | 35.129091 (Ohio) | Primary |
| 207R00000X | Internal Medicine | 2013018168 (Missouri) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Marymount Hospital | Garfield heights, OH | Hospital |
| Cleveland Clinic | Cleveland, OH | Hospital |
| Hillcrest Hospital | Mayfield heights, OH | Hospital |
| Akron General Medical Center | Akron, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Cleveland Clinic Foundation | 1850203555 | 5690 |
News Archive
Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.
Conventional wisdom has long been negative on Africa. Historically, it has been seen as a failing continent, plagued by deep-rooted problems - poverty, corruption, war, and disease. But after four decades of relative stagnation, Africa has been growing rapidly. Since the 1990s, many African countries have seen economic and political improvements, more transparent elections, increased democracy and freedom of press. But these successes are not well understood.
Rearrangements of chromosome 3q26.2 have a significant negative impact on patients with chronic myeloid leukaemia, suggests research published in Blood.
Researchers from Albert Einstein College of Medicine of Yeshiva University and other institutions have developed a potential antibody therapy for Sudan ebolavirus (SUDV), one of the two most lethal strains of Ebola.
› Verified 4 days ago
| Entity Name | The Cleveland Clinic Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1679525919 PECOS PAC ID: 1850203555 Enrollment ID: O20031103000049 |
News Archive
Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.
Conventional wisdom has long been negative on Africa. Historically, it has been seen as a failing continent, plagued by deep-rooted problems - poverty, corruption, war, and disease. But after four decades of relative stagnation, Africa has been growing rapidly. Since the 1990s, many African countries have seen economic and political improvements, more transparent elections, increased democracy and freedom of press. But these successes are not well understood.
Rearrangements of chromosome 3q26.2 have a significant negative impact on patients with chronic myeloid leukaemia, suggests research published in Blood.
Researchers from Albert Einstein College of Medicine of Yeshiva University and other institutions have developed a potential antibody therapy for Sudan ebolavirus (SUDV), one of the two most lethal strains of Ebola.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Timothy Brian Lumpkin, MD 4901 Forest Park Ave, Saint Louis, MO 63108-1402 Ph: (314) 362-5060 | Dr Timothy Brian Lumpkin, MD 12300 Mccracken Rd Ste 259, Garfield Heights, OH 44125-2914 Ph: (216) 587-8830 |
News Archive
Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.
Conventional wisdom has long been negative on Africa. Historically, it has been seen as a failing continent, plagued by deep-rooted problems - poverty, corruption, war, and disease. But after four decades of relative stagnation, Africa has been growing rapidly. Since the 1990s, many African countries have seen economic and political improvements, more transparent elections, increased democracy and freedom of press. But these successes are not well understood.
Rearrangements of chromosome 3q26.2 have a significant negative impact on patients with chronic myeloid leukaemia, suggests research published in Blood.
Researchers from Albert Einstein College of Medicine of Yeshiva University and other institutions have developed a potential antibody therapy for Sudan ebolavirus (SUDV), one of the two most lethal strains of Ebola.
› Verified 4 days ago
Dr. Lisa Dicristofaro, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 12000 Mccracken Rd, Suite 550, Garfield Heights, OH 44125 Phone: 216-581-8369 Fax: 216-663-0666 | |
Edward Steven Rosenthal, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 12000 Mccracken Rd, #453, Garfield Heights, OH 44125 Phone: 216-581-4900 Fax: 216-581-7370 | |
Henry Makepeace, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 12300 Mccracken Rd, Garfield Heights, OH 44125 Phone: 216-581-0500 | |
Dr. Amir Alamir, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 12000 Mccracken Rd, Suite 157, Garfield Heights, OH 44125 Phone: 216-510-4765 Fax: 216-510-5046 | |
Dr. Devon Zoller, Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 5595 Transportation Blvd Ste 220, Garfield Heights, OH 44125 Phone: 216-536-6614 | |
Dr. John Jabbour, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 12000 Mccracken Rd, Suite 108, Garfield Heights, OH 44125 Phone: 216-584-7234 Fax: 216-584-7236 |